We identify and share funding opportunities as they arise to help advance MPT research and development. The items below are listed from the earliest to latest application due dates. We encourage you to browse below and contact us if you hear of any new opportunities.


Multipurpose Prevention Technology: Novel Systemic Options for Young Adults (R43/R44 Clinical Trial Not Allowed)

The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative long-acting systemic and non-systemic multipurpose prevention technologies (MPT). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods) in adolescent and young women. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies. It also encourages biobehavioral and behavioral/social studies to identify MPT end user preferences factors (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT use in adolescent and young women. This is a R41/R42 – Small Business Technology Transfer (STTR) Grant – Phase I, Fast-Track. View the full FOA description, and apply here before December 9th, 2021.


Multipurpose Prevention Technology (MPT): Novel Systemic Options for Young Adults (R41/R42 Clinical Trial Not Allowed)

The objective of this FOA is to support the development of innovative long-acting systemic and non-systemic MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods) in adolescent and young women. Applications for MPT development may involve pharmacokinetic (PK), pharmacodynamic (PD), safety and, drug-drug interactions (DDI) studies. It also encourages biobehavioral and social studies to identify MPT end user preferences (look, feel, effectiveness, safety and duration of action) and other behavioral/social factors that could promote increased MPT use in adolescent and young women. This is a R43/R44 – Small Business Innovation Research (SBIR) Grant – Phase I and Fast-Track. View the full FOA description and apply before December 9th, 2021 here.


Contraception Development Research Center Program

This funding opportunity announcement (FOA) supports and facilitates multidisciplinary approaches towards the development of new and/or improved contraceptive methods for both men and women through the formation of a Contraceptive Research Development Center. This FOA also allows the inclusion of translational studies to facilitate the pre-clinical to clinical transition and increase the likelihood of clinical success. Additionally, it allows for behavioral/social science, including market research to test user acceptability, research projects that are responding and well-coordinated to the contraceptive product being developed.  The Center will serve as a national resource for development of early stage investigators electing to pursue careers in contraceptive research. Applications are due December 29th, 2021; learn more and apply here.

  • Applications of high program priority include: Applications focused on the late stage preclinical or clinical development of a single non-hormonal multipurpose prevention technology (MPT, a product with both contraceptive and anti-infective properties)

Biological Testing Facility (X01 Clinical Trial Not Allowed)

The Eunice Kennedy Shriver National Institute of Child Health and Human Development’s (NICHD) state-of-the art Biological Testing Facility supports female and/or male non-hormonal contraception development, including MPTs. This opportunity is to support the enablement of an IND/IDE study of a pre-clinical candidate that offers a safe, non-hormonal based therapy for female and/or male contraception that acts prior to fertilization and does not act via the hypothalamic-pituitary-gonadal axis. Additional details can be found at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: PAR-21-078, then clicking on the opportunity number.

  • Funding Opportunity #: PAR-21-078
  • Open Date: 15 December 2020
  • Letters of Intent Due: Not Applicable
  • Application Due: 14 January 2022, 15 July 2022

Family Planning and Reproductive Health Methods APS

The United States Agency for International Development (USAID) is seeking to support the research, development, and introduction of technologies and approaches that better meet the needs of women as their sexual and reproductive health concerns change over time. This includes the development of multipurpose prevention technologies (MPTs) that address the simultaneous risks of unintended pregnancy, HIV, and other sexually transmitted infections (STIs)—particularly Herpes Simplex Virus (HSV) and Human Papillomavirus (HPV). Additional details can be found on the Round 4 call for concept papers at www.GRANTS.gov by searching within “Search Grants” for Funding Opportunity Number: SOL-OAA-13-000024, then clicking on the opportunity number.

  • Funding Opportunity #: SOL-OAA-13-000024
  • Open Date: 15 January 2013
  • Closing Date: 14 January, 2023
  • Round 5 funding not yet announced

Comprehensive Resources for HIV Microbicides and Biomedical Prevention (CRMP)

This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical prevention (nBP) strategies and products. The types of nBPs supported include, but are not limited to, topical microbicides, pre-exposure prophylaxis (PrEP) and Multipurpose Prevention Technologies (MPT’s) for the purpose of preventing HIV transmission and acquisition in adolescents, women, men and transgender individuals. Sponsors seeking these services receive no funding from NIAID, but instead receive products or information generated by NIAID-funded contractors on their behalf. Data and reports are provided in a format that supports a regulatory filing. Additional details can be found here.

  • Who can use this resource?
    • Sponsors must have a defined need or gap that is delaying or blocking further advancement of their product to clinical testing and/or licensure.
    • Sponsors need preliminary data and/or regulatory agency input supporting a justification for the requested support.
    • If in support of a specific grant activity, the Sponsor needs to demonstrate a critical need to the advancement of the grant objectives that cannot be met by rebudgeting or administrative supplement, if applicable.  
  • How to get started: Follow the procedures for requesting access to NIAID contract services
  • Application Due: Rolling basis

MCI-BCM Sponsored Target Screening

This ongoing funding scheme offers the opportunity to utilize state-of-the-art facilities at Baylor College of Medicine to screen validated male contraceptive targets for small-molecule inhibitors using DNA-Encoded Chemistry Technology. Applications are accepted on an ongoing, rolling basis. Learn more and apply here.